Think about a future with no extra momentary morgues outdoors hospitals.

Preliminary outcomes on a third coronavirus vaccine, this one from AstraZeneca and the College of Oxford, present promise. That is no much less thrilling for being the third, behind Pfizer and Moderna: The coronavirus pandemic is a problem too massive to be shortly ended by one efficient vaccine. We want each potential software in opposition to it, and AstraZeneca’s has some key benefits.

The vaccine confirmed common 70% effectiveness throughout trials of two totally different dosages. Curiously, the much less efficient routine, at 62%, used two full doses a month aside, whereas the simpler possibility, at 90%, was a half dose adopted by a full dose a month later. If that end result holds, it might imply extra individuals being vaccinated. Importantly, it’s less expensive than both the Pfizer or Moderna vaccines, and could be saved at regular fridge temperatures, whereas the others can solely be saved at fridge temperature for a restricted time.